Elliott makes $7B all-cash bid for Athenahealth

| | Health Exec | Policy & Regulations

According to CNBC, Elliott Management made an all-cash deal for Athenahealth on Monday morning. Elliott’s bid is for $160 a share—a 27 percent premium to the Massachusetts-based healthcare technology company’s Friday afternoon price.

Athenahealth shares were up sharply in Monday trading after initial reports of a possible deal.

Elliott released a letter to Athenahealth on Monday, claiming his firm has had constructive discussions with management, "and we greatly appreciate how much time the management team, led by Jonathan, and the [b]oard have invested in evaluating our perspectives as well as the perspectives of our fellow shareholders."

Paul Singer's Elliott makes all-cash offer for Athenahealth of $160 a share

But Elliot continued, “Unfortunately, we are faced now with the stark reality that athenahealth as a public-company investment, despite all of its promise, has not worked for many years, is not working today and will not work in the future. Given athenahealth's potential, this reality is deeply frustrating."

CNBC is reporting the deal could be worth $7 billion, including debt.

Read more at the link below:

Related Content

To tell or not to tell: Do patients really need to know who—or what—writes their doctor’s notes?
CMS ends ACA special enrollment, changes deadline for signing up
Report: NIH continues to pull research grants, in violation of court orders
HHS sends 80K workers a $25K ‘voluntary’ resignation notice
More than 1,000 hospitals earn $700M opioid crisis judgment
VA planning 83,000 layoffs as part of restructuring

Around the web

Cardiovascular Business
Boston Scientific enters renal denervation market with acquisition worth up to $540M

Boston Scientific has announced another significant M&A deal, scooping up an Israeli medtech company focused on RDN technology. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
FDA announces catheter recall for Johnson & Johnson PFA system due to stroke risk

The recall comes after approximately 3% of patients treated with the device during the early stages of its U.S. rollout experienced a stroke or transient ischemic attack following surgery. The expected stroke rate is closer to 1%, the FDA explained.